Asceltis receives China IND nod for clinical trials of ASC42 for CHB
Category: #health  By Pankaj Singh  Date: 2021-06-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Asceltis receives China IND nod for clinical trials of ASC42 for CHB

Elevating cases of chronic hepatitis B (CHB) has now impelled Asceltis Pharma Inc., a data driven biotech firm in China, to experiment towards developing drugs that can, to some extent, reduce the impact of CHB in the human body.

In light of this, the company recently announced that China National Medical Products Administration produced an Investigational New Drug (IND) approval for its drug candidate- ASC42 to undertake clinical trials for the CHB indication.

For the record, ASC42 is an in-house developed, potent, selective FXR agonist. It is an oral formulation advanced with in-house patent technology, which is considered to be stable at room temperature.

It has been reported that both in-vitro primary human hepatocyte cells and in-vivo HBV/AAV mouse studies, earlier, presented that the ASC42 drug candidate significantly repressed serum hepatitis B antigen and HBV pregenomic RNA. This implies that ASC42 boasts of therapeutic potential to cure CHB.

Reports suggest that as an FXR agonist, ASC42 has exceptional operation against HBV as it prevents the transcription of HBV cccDNA into HBV RNA, in turn repressing the translation of HBV RNA into HBsAg.

Apparently, the ASC42 drug is also likely to reduce HBV cccDNA stability.

It would be crucial to mention that ASC42 is the second investigational new drug of the company for HBV functional cure. Another investigational new drug for HBV cure is ASC22, which is currently in Phase IIb analysis. The study showcased preliminary efficacy and good safety in HBsAg reduction in Phase IIa evaluation.

Commenting on the latest accomplishment, Founder, Chairman and CEO of Asceltis, Dr. Jinzi J. stated that the firm is quite thrilled about ASC42 IND nod for CHB. Dr. Jinzi addressed this achievement as a key milestone for its CHB functional cure pipeline. He further added that the potential synergy between ASC22 and ASC42 is promising for the company’s effort on CHB functional cure.

Source Credit: https://www.prnewswire.com/news-releases/ascletis-received-china-ind-approval-of-its-fxr-agonist-asc42-for-chronic-hepatitis-b-indication-301306416.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Samsung rolls out its expanded 2021 Odyssey gaming monitor range
Samsung rolls out its expanded 2021 Odyssey gaming monitor range
By Pankaj Singh

Samsung Electronics, one of the leading players in the gaming monitor market, has reportedly announced the commercial launch of its expanded 2021 lineup of Odyssey gaming monitor. Following the launch of its curve-shaped gaming monitor in 2020, the c...

Indonesia to only sell electric motorcycles and vehicles by 2050
Indonesia to only sell electric motorcycles and vehicles by 2050
By Pankaj Singh

The country is seeking to increase the processing of nickel laterite ore which is used in lithium batteries In a bid to reduce carbon emission levels, the Energy Minister of Indonesia, Arifin Tasrif has announced that the nation is planning to only ...

Amway announces Rs 170 crore investment in India over 2-3 years
Amway announces Rs 170 crore investment in India over 2-3 years
By Pankaj Singh

Nutraceuticals giant, Amway, has reportedly made it to the front page following its recent announcement of investing a whopping Rs 170 crore in the Indian sub-continent over the next 2 to 3 years, in an attempt to boost the research and development, ...